A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

PHASE2CompletedINTERVENTIONAL
Enrollment

233

Participants

Timeline

Start Date

July 13, 2018

Primary Completion Date

October 21, 2019

Study Completion Date

October 21, 2019

Conditions
Schizophrenia
Interventions
DRUG

ASP4345

oral administration

DRUG

placebo

oral administration

DRUG

risperidone

oral or depot administration

DRUG

quetiapine

oral administration

DRUG

olanzapine

Oral or depot administration

DRUG

ziprasidone

Oral or depot administration

DRUG

aripiprazole

Oral or depot administration

DRUG

brexpiprazole

Oral administration

DRUG

paliperidone

Oral or depot administration

DRUG

lurasidone

Oral administration

Trial Locations (27)

10032

New York State Psychiatric Institute, New York

10035

Manhattan Psychiatric Center's 125th Street Clinic, New York

11235

SPRI Clinical Trials, LLC, Brooklyn

11432

CNS Research Science, Inc., Jamaica

14618

Finger Lakes Clinical Research, Rochester

30328

Radiant Research, Inc., Atlanta

30331

Atlanta Center for Medical Research, Atlanta

45417

Midwest Clinical Research Center, Dayton

48105

Michigan Clinical Research Institute PC, Ann Arbor

49503

Cherry Street Services, Inc., Grand Rapids

60612

Alam Medical Research Inc., Chicago

60640

Uptown Research Institute, Chicago

63118

Arch Clinical Trials, LLC, St Louis

75080

Pillar Clinical Research, LLC, Richardson

75115

InSite Clinical Research, LLC, DeSoto

78754

Community Clinical Research, Inc., Austin

87109

Albuquerque Neuroscience Inc., Albuquerque

90502

Collaborative Neuroscience Network, LLC, Torrance

90660

California Neuropsychopharmacology Clinical Research Institute-LA, LLC, Pico Rivera

90703

CNS Research Science, Inc., Cerritos

91945

Synergy East, Lemon Grove

92102

California Neuropsychopharmacology Clinical Research Institute, LLC (CNRI-San Diego), San Diego

92103

Artemis Institute for Clinical Research, San Diego

92123

Sharp Mesa Vista Hospital, San Diego

92845

Collaborative Neuroscience Network, LLC, Garden Grove

94607

Pacific Research Partners, LLC, Oakland

08009

Hassman Research Institute, Berlin

All Listed Sponsors
lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT03557931 - A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication | Biotech Hunter | Biotech Hunter